U.S. Markets closed
S&P Futures
3,837.75-8.25(-0.21%)Dow Futures
31,000.00-82.00(-0.26%)Nasdaq Futures
13,358.50-37.00(-0.28%)
Aptevo Therapeutics Inc. (APVO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
33.12+1.55 (+4.91%)
At close: 4:00PM EST
33.92 +0.80 (2.42%)
After hours: 7:32PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 31.57 |
| Open | 31.21 |
| Bid | 32.83 x 800 |
| Ask | 33.55 x 900 |
| Day's Range | 30.71 - 33.54 |
| 52 Week Range | 2.94 - 60.00 |
| Volume | 110,257 |
| Avg. Volume | 1,819,877 |
| Market Cap | 145.025M |
| Beta (5Y Monthly) | 7.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.84 |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 65.67 |
- ACCESSWIRE
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRâ„¢ and ADAPTIR-FLEXâ„¢ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
- Zacks
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- ACCESSWIRE
Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm
PHILADELPHIA, PA / ACCESSWIRE / December 19, 2020 / Kaskela Law LLC announces that it is investigating Aptevo Therapeutics Inc.
© 2021 Verizon Media. All rights reserved.
